Dr Damian O'Connell is an executive director of Pfizer and is global clinical leader for the company's analgesic portfolio. Accomplished in senior leadership roles and strategic pharmaceutical development and knowledge, Dr O'Connell was previously head of experimental medicine at the Pfizer Global Research and Development laboratory in Kent, UK. Before that, he worked as international drug director for Warner-Lambert.
Dr O'Connell, who has both MD and PhD degrees from the National University of Ireland, has been a medical faculty member of the University of Virginia Health Sciences Centre, as well as being a member of the Clinical Pharmacology and Therapeutics Department at University College Cork. He serves as a member of the experimental medicine and safety biomarker committees of the Association of the British Pharmaceutical Industry and was a rapporteur for the efficacy component of the recently published 'Innovative Medicines Initiative'.
In addition, Dr O'Connell is a Fellow of the Royal Academy of Medicine in Ireland; he is a member of the British Pharmacological Society, the American Society for Clinical Pharmacology and Therapeutics, the American College of Clinical Pharmacology and the Irish Association of Pharmacologists.